T
SGMO

Transce3nd’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Transce3nd’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,000
Closed -$541 – 962
2025
Q2 		$541 Hold
1,000
– – ﹤0.01% 1070
2025
Q1 		$656 Hold
1,000
– – ﹤0.01% 1008
2024
Q4 		$1.02K Buy
+1,000
New +$1.83K ﹤0.01% 1210

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Transce3nd's SGMO Position: Q3 2025 in Review

Transce3nd sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2025, closing a stake of 1,000 shares — an estimated $541 sold.

Transce3nd first reported a position in SGMO in Q4 2024 and held it in 3 quarters. The position peaked at $1.02K in Q4 2024. 112 funds tracked by Wall St. Rank hold SGMO as of Q3 2025.

  • Transce3nd reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2025 after selling out during the quarter.
  • Transce3nd sold 1,000 SANGAMO THERAPEUTICS INC shares in Q3 2025, an estimated $541.
  • Transce3nd first reported a position in SANGAMO THERAPEUTICS INC in Q4 2024 and held it in 3 quarters.
  • Transce3nd's SANGAMO THERAPEUTICS INC position peaked at $1.02K in Q4 2024.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2025.

Based on Transce3nd's 13F filing for Q3 2025, filed 12 Nov 2025.